STOCK TITAN
  1. Home
  2. News
  3. MRTX

Mirati Therapeut (MRTX) Stock News, Jul-Aug 2023

MRTX Nasdaq
News

Mirati To Present Pooled Clinical Data from Adagrasib's KRYSTAL-1 Study Demonstrating Overall Survival Results at Two-Years of Follow-Up at 2023 World Conference on Lung Cancer

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.53%
Tags
conferences clinical trial
-
News

Mirati Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.96%
Tags
offering
-
News

Cancer Discovery Publishes Preclinical and Initial Clinical Data for MRTX1719 to Treat MTAP-Deleted Cancers through Novel Approach to MTA-Cooperative PRMT5 Inhibition

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.95%
Tags
clinical trial
News

Mirati Therapeutics Announces Pricing of Upsized Public Offering

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.09%
Tags
offering
-
News

Mirati Therapeutics Announces Proposed Public Offering

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.09%
Tags
offering
-
News

Mirati Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Updates

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.09%
Tags
earnings
News

Mirati Therapeutics Announces Departure of Chief Executive Officer David Meek

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.09%
Tags
none
-
News

Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.91%
Tags
none
-
News

Mirati Therapeutics® to Report Second Quarter 2023 Financial Results and Recent Corporate Updates on August 8, 2023

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.9%
Tags
conferences earnings
News

Mirati Therapeutics Provides Update on Regulatory Review in the European Union of KRAZATI (adagrasib) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRAS G12C Mutation

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.39%
Tags
none